Hyeong-Won Seo

Hyeong-Won Seo

Auto-generated profile, based on publicly available information

Hyeong-Won Seo

Affiliation International Vaccine Institute, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SJSuchada Jiamsiri
Suchada Jiamsiri
CRChulwoo Rhee
Chulwoo Rhee
HAHyeon Seon Ahn
Hyeon Seon Ahn
NPNimesh Poudyal
Nimesh Poudyal
HSHyeong-Won Seo
Hyeong-Won Seo
JLJulia Lynch
Julia Lynch
Human papillomavirus (HPV) is a common infection principally spread through sexual activity. Most HPV infections are asymptomatic and resolve spontaneously. However, persistent infection may progress to cervical cancer. Highly efficacious HPV vaccines have been available since 2006, yet uptake into national programs has been slow in part due to cost. WHO guidelines call for a two-dose (0,6 month) schedule for girls 9–14 years of age. Post-hoc analyses of randomized trials have found high vaccine effectiveness following a single dose of vaccine. In order to provide additional data on the potential impact of single dose HPV vaccination in a real-world setting, we are conducting an effectiveness study among Thai schoolgirls. This is an observational study of a single dose (SD) or two doses (2D) of the bivalent HPV vaccine CERVARIX® (GlaxoSmithKline plc.) administered in a school-based program to 8–9,000 Grade 8 female students in two provinces of Thailand beginning in 2018; one province is assigned the SD, and the other the standard 2D regimen. The reduction in HPV vaccine-type prevalence will be assessed in each province two and four years after vaccination by comparing HPV prevalence in urine samples obtained through cross-sectional surveys of the immunized grade cohort as they age and compared to a historical “baseline” HPV prevalence of same age students.